

# Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

## CD16-Biotin, human

RRID:AB\_2655422

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-106-700, RRID:AB\_2655422

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2655422](http://antibodyregistry.org/AB_2655422)

**Proper Citation:** Miltenyi Biotec Cat# 130-106-700, RRID:AB\_2655422

**Target Antigen:** CD16

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Discontinued: 7-2018; Target Distribution NK cells, monocytes, granulocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-391. (RRID:AB\_2751110).

**Antibody Name:** CD16-Biotin, human

**Description:** This monoclonal targets CD16

**Target Organism:** non-human primate, human

**Clone ID:** REA423

**Antibody ID:** AB\_2655422

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-106-700

**Record Creation Time:** 20250820T040046+0000

**Record Last Update:** 20250820T174748+0000

---

## Ratings and Alerts

No rating or validation information has been found for CD16-Biotin, human.

**Warning:** Discontinued: 2021

Discontinued: 7-2018; Target Distribution NK cells, monocytes, granulocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-391. (RRID:AB\_2751110).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464.